8,000-12,000 estimated GCC IgAN patients narrow through a biopsy bottleneck that catches fewer than 30% of eligible cases, then to zero patients on any novel agent, since none is SFDA-registered as of 2024.
The GCC IgAN funnel starts with an estimated 8,000-12,000 patients across the region, a figure drawn from a nephrology network capacity survey rather than a national disease registry, since no GCC country maintains one specific to IgAN. The first and steepest narrowing happens at diagnosis. KDIGO guidance calls for kidney biopsy in non-diabetic proteinuria, yet the same capacity survey finds GCC nephrology practice performing biopsy in fewer than 30% of eligible proteinuric patients, against roughly 70% in Japan and Germany. Biopsy capability itself is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams, and the region's 20-25% adult diabetes prevalence means most proteinuric patients are attributed to diabetic nephropathy by default, without ever reaching a biopsy that could confirm IgAN instead.
The second narrowing is total: as of 2024, neither budesonide (Tarpeyo, US accelerated approval 2021) nor sparsentan (Filspari, US accelerated approval 2023) is SFDA-registered anywhere in the GCC, so the on-novel-therapy count for this funnel is zero, not a small number, zero. GCC IgAN patients today are managed entirely on ACEi/ARB and increasingly SGLT2i background therapy. This model is deliberately built to stop at that honest zero rather than infer a treated count from US or European penetration rates that do not transfer to a market with no registered agent. What it can size precisely is the diagnostic bottleneck itself: the 12-24 month proteinuria-to-diagnosis pathway (roughly double Europe's 6-12 month benchmark), the fewer-than-20-centre biopsy capacity ceiling, and the small, identifiable nephrology KOL population, some 300 GCC nephrologists in total, 30-50 with glomerular-disease subspecialty interest, concentrated at KFSH&RC, HMC Doha, AUH, King Fahd Hospital Jeddah, and University Hospital Sharjah, who would be the first prescribers once an agent is registered.
GCC IgAN funnel — from estimated prevalence to a formally empty treated population
| Funnel Stage | Population | Source |
|---|---|---|
| Estimated GCC IgAN prevalence | 8,000-12,000 | GCC nephrology network capacity survey 2022 |
| Eligible proteinuric patients biopsied | Fewer than 30% | GCC nephrology network capacity survey 2022, vs ~70% Japan/Germany |
| Time from proteinuria detection to diagnosis | 12-24 months | GCC nephrology network capacity survey 2022, vs 6-12 months Europe |
| Patients on an SFDA-registered novel IgAN agent | 0 | SFDA drug registration database query, 2024 |
Sources: GCC nephrology network capacity survey 2022; SFDA drug registration database query 2024; KDIGO 2021 IgAN guideline; Gulf renal registry 2022; Saudi Society of Nephrology membership data.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Prevalence estimate methodology
- the diabetes-attribution masking effect
- biopsy-rate benchmarking against KDIGO 2021 guideline standards and GCC nephrology network capacity survey data
Delivers
- SFDA registration status for budesonide and sparsentan as of 2024
- why the model states zero rather than inferring a penetration rate from US or European data
- the pre-launch forecasting implication
Delivers
- Fewer-than-20-centre biopsy capability map
- the 12-24 month proteinuria-to-diagnosis pathway
- the 30-50 subspecialist GCC nephrologist KOL list
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the biopsy bottleneck, not prevalence uncertainty, is the constraint a GCC launch plan must solve first
- Pressure-tested against the honest zero at the treated end of the funnel
- 8,000-12,000 estimated GCC IgAN patients (nephrology network capacity survey)
- Why no national IgAN-specific registry exists across the GCC
- Fewer than 30% of eligible proteinuric patients biopsied, versus ~70% in Japan/Germany
- Diabetes-attribution masking and the fewer-than-20-centre biopsy capacity ceiling
- 12-24 months proteinuria-to-diagnosis, versus 6-12 months in Europe
- Referral-pathway steps that add delay at each stage
- SFDA registration status for budesonide and sparsentan as of 2024
- ACEi/ARB and SGLT2i background therapy as the current standard of care
- Which assumptions move the diagnosed pool most
- Scenario ranges tied to biopsy-capacity expansion
- Patient volume by horizon once SFDA registration completes, under conservative, base, and aggressive scenarios
- KOL and centre-level prescriber sequencing
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel, population, disease burden (E1), diagnosis and specialist capture (E2), diagnostic delay (E3), and treatment reality (E4), delivered as a live Excel workbook. Where a stage of the funnel resolves to zero or to an unregistered market, the model states that explicitly rather than substituting a borrowed penetration rate from another market.
GCC IgA nephropathy patient flow sources: GCC nephrology network capacity survey 2022, SFDA drug registration database query 2024, KDIGO 2021 IgAN guideline, Gulf renal registry 2022, and Saudi Society of Nephrology membership and congress programme data.
- GCC IgAN prevalence estimate verified against the GCC nephrology network capacity survey 2022
- Biopsy rate and centre-capacity figures verified against the GCC nephrology network capacity survey 2022, benchmarked to KDIGO 2021 guideline standards
- Zero-registered-agent status confirmed against the SFDA drug registration database query, 2024
- A hard biopsy-confirmed IgAN count is a genuine data gap flagged for a future model update; no figure was invented in its place, the diagnosed pool in this model is bounded by the biopsy-rate estimate, not asserted as a fixed count
Frequently asked questions
Commission this model
AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC IgA nephropathy opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms funnel scope and biopsy-capacity assumptions before building.
Research-verified patient flow model in 72 hours with optional analyst readout.